Meeting
2014 ASCO Annual Meeting
Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.
Authors
Nikhil Wagle
Dana-Farber Cancer Institute, Boston, MA
Nikhil Wagle , Nancy U. Lin , Andrea L. Richardson , Ignaty Leshchiner , Ingrid A. Mayer , Andres Forero-Torres , Timothy J. Hobday , Elizabeth Claire Dees , Rita Nanda , Mothaffar F. Rimawi , Hao Guo , William Thomas Barry , Antonio C. Wolff , Stacey B. Gabriel , Levi A. Garraway , Eric P. Winer , Ian E. Krop
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 536)
DOI
10.1200/jco.2014.32.15_suppl.536
Abstract #
536
Poster Bd #
26
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data.
First Author: Erika Paige Hamilton
Poster
2019 ASCO Annual Meeting
Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.
First Author: Ning Liao
Poster
2016 ASCO Annual Meeting
A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer.
First Author: Nikhil Wagle
Poster
2014 ASCO Annual Meeting
Evidence of PIK3CA and TP53 co-mutation in breast cancer identification on next-generation sequencing (NGS) of ERBB2 (HER2)-amplified residual disease following preoperative anti-HER2 therapy.
First Author: Frankie Ann Holmes